Position paper: new insights into the immunobiology and dynamics of tumor–host interactions require adaptations of clinical studies. Issue 8 (2nd August 2020)

• Record Type: Journal Article
• Authors: Sprenger, Tobias; Schirrmacher, Volker; Stücker, Wilfried; van Gool, Stefaan W
• Is Part Of: Expert review of anticancer therapy. Volume 20:Issue 8(2020)
• Page Start: 639
• Page End: 646
• Publication Date: 2020-08-02
• Subjects: Cancer immunotherapy -- guidelines -- conflict of interest -- randomized trials -- tumor immunology -- evidence-based medicine -- dendritic Cells -- newcastle Disease Virus; Cancer -- Treatment -- Periodicals; 616.99406
• DOI: 10.1080/14737140.2020.1785874
• Languages: English
• ISSNs: 1473-7140

Abstract

ABSTRACT: Introduction: Prospective double-blind placebo-controlled randomized clinical trials (RCTs) are considered standard for the proof of the efficacy of oncologic therapies. Molecular methods have provided new insights into tumor biology and led to the development of targeted therapies. Due to the increasing complexity of molecular tumor characteristics and of the individuality of specific anti-tumor immune reactivity, RCTs are unfortunately only of limited use. Areas covered: The historical methods of drug research and approval and the related practices of reimbursement by statutory and private health insurance companies are being questioned. New, innovative methods for the documentation of evidence in personalized medicine will be addressed. Possible perspectives and new approaches are discussed, in particular with regard to glioblastoma. Expert opinion: Highly specialized translational oncology groups like the IOZK can contribute to medical progress and quick transfer 'from bench to bedside.' Their contribution should be acknowledged and taken into account more strongly in the development of guidelines and the reimbursement of therapy costs. Methodological plurality should be encouraged.